Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-01-07 @ 12:13 PM
Study NCT ID:
NCT00865605
Status:
COMPLETED
Last Update Posted:
2010-08-17
First Post:
2009-03-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C064466', 'term': 'halobetasol'}, {'id': 'D009824', 'term': 'Ointments'}], 'ancestors': [{'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 71}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2003-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-08', 'completionDateStruct': {'date': '2004-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2010-08-13', 'studyFirstSubmitDate': '2009-03-17', 'studyFirstSubmitQcDate': '2009-03-18', 'lastUpdatePostDateStruct': {'date': '2010-08-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2009-03-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2004-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Primary outcome: Vasoconstrictor Response', 'timeFrame': '36 hours'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['bioequivalence', 'Vasoconstriction', 'Halobetasol', 'Healthy subjects'], 'conditions': ['Healthy']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.).', 'detailedDescription': 'Study Type: Interventional Study Design: A single blind, single-exposure study on healthy adult male and female subjects.\n\nOfficial Title: A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study\n\nFurther study details as provided by Actavis Elizabeth LLC:\n\nPrimary Outcome Measures:\n\nVasoconstrictor Response'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Subject understands the study, is willing to participate, and gives written informed consent.\n* Subject demonstrates adequate vasoconstriction to the screening topical corticosteroid Halobetasol propionate 0.05% ointment within 30 days of dosing.\n* Subject is a non-smoking (minimum of 14 days), male or female, ages of 18 - 65 years, inclusive.\n* Subject is within 20% of their ideal body weight as defined by the 1999 Metropolitan Life Insurance Company Height and Weight Tables.\n* Subject is judged by the Investigator to be healthy on the basis of pre-study medical history.\n* Subjects of child-bearing potential agree to use an acceptable method of birth control during study participation (e.g. abstinence, any prescribed birth control method, double barrier method, Le. condom plus foam, condom plus diaphragm).\n* Subject is willing to refrain from excessive consumption of sodium in food or beverage 48hrs before and for the duration of the study.\n* Subject is willing to shower using the same soap/cleansers for the duration of the study.\n* Subject is willing to follow study restrictions.\n\nExclusion Criteria:\n\n* Subject has a past or current medical condition that might significantly affect pharmacodynamic response to topical corticosteroids.\n* Subject has diabetes mellitus, clinically significant hypertension or circulatory disease.\n* Subject is taking any medication on a regular basis that could modulate blood flow (constrictor or dilator), with the exception of any prescribed birth control method and hormone replacement therapy. Examples of such drugs include nitroglycerin, anti- hypertensives, antihistamines, NSAIDs, aspirin, phenylpropanolamine, phentolamine or any other medications deemed inappropriate by the Investigator.\n* Subject is planning to use any exclusionary over-the-counter (OTC) medications within 48 hours prior to or throughout the study that could modulate vascular blood flow.\n* Subject intends to start, stop or change dose of any prescription or OTC medication within 48 hours prior to or throughout the study. Acetaminophen may be administered, if needed.\n* Subject has used prescription or OTC topical medications on the ventral forearms within 1 month prior to study conduct.\n* Subject has a history of sensitivity/allergy to the ingredients found in the test formulations or has a history of adverse reactions to topical or systemic corticosteroids.\n* Subject has a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.\n* Subject has a history of significant skin conditions or disorders, for example, psoriasis, atopic dermatitis, etc.\n* Subject has a history of significant dermatologic cancers, for example, melanoma or squamous cell carcinoma. Basal cell carcinomas that were superficial and do not involve the investigative site are acceptable.\n* Subject has an obvious difference in skin color between arms or the presence of a skin condition, scar tissue, tattoo or coloration that would interfere with placement of test sites, their assessments, their reaction to drug or could compromise the safety of the subject.\n* Subject has used topical medications on the ventral forearms within 1 month prior to dosing.\n* Subject has used a tobacco product within 14 days of study conduct.\n* Subject has a clinically significant history of drug abuse or alcoholism.\n* Subject has donated or received blood within 30 days prior to dosing.\n* Subject's caffeine intake is greater than 500 mg per day (1 cup of coffee contains approximately 85 mg of caffeine).\n* Subject is unwilling to abstain from alcohol or caffeine for 48 hours prior to and throughout the study.\n* (Females only): Subject is pregnant or lactating.\n* Subject has participated in another investigational drug, medical device, or biologics study within 30 days prior to dosing."}, 'identificationModule': {'nctId': 'NCT00865605', 'briefTitle': 'Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects', 'organization': {'class': 'INDUSTRY', 'fullName': 'Actavis Inc.'}, 'officialTitle': 'A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study', 'orgStudyIdInfo': {'id': 'DP03-689'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A', 'description': 'Halobetasol Propionate 0.05% Ointment, single exposure', 'interventionNames': ['Drug: Halobetasol Propionate 0.05% Ointment, single exposure']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'B', 'description': 'Ultravate® 0.05% ointment, single exposure', 'interventionNames': ['Drug: Ultravate® 0.05% ointment, single exposure']}], 'interventions': [{'name': 'Halobetasol Propionate 0.05% Ointment, single exposure', 'type': 'DRUG', 'otherNames': ['Halobetasol'], 'description': 'A: Other Subjects received Alpharma/Purepac USHP formulated products', 'armGroupLabels': ['A']}, {'name': 'Ultravate® 0.05% ointment, single exposure', 'type': 'DRUG', 'otherNames': ['Halobetasol'], 'description': 'Subjects received Bristol-Myers Squibb Company formulated products', 'armGroupLabels': ['B']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92128', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'DermTech International', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}], 'overallOfficials': [{'name': 'Paul A. Lehman,, M.Sc.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'DermTech International'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Actavis Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Christine Winslow, Director of Clinical Development', 'oldOrganization': 'Actavis Inc'}}}}